| Literature DB >> 29209277 |
Marie Pereira1, Stephanie Gohin1, Jean-Paul Roux2, Amy Fisher3, Mark E Cleasby1, Guillaume Mabilleau4, Chantal Chenu1.
Abstract
<span class="Disease">Type 2 diabetes mellitus (T2DM) is associated with skeletal complications, including an increased risk of <span class="Disease">fractures. Reduced blood supply and bone strength may contribute to this skeletal fragility. We hypothesized that long-term administration of Exenatide, a glucagon-like peptide-1 receptor agonist, would improve bone architecture and strength of T2DM mice by increasing blood flow to bone, thereby stimulating bone formation. In this study, we used a model of obesity and severe T2DM, the leptin receptor-deficient db/db mouse to assess alterations in bone quality and hindlimb blood flow and to examine the beneficial effects of 4 weeks administration of Exenatide. As expected, diabetic mice showed marked alterations in bone structure, remodeling and strength, and basal vascular tone compared with lean mice. Exenatide treatment improved trabecular bone mass and architecture by increasing bone formation rate, but only in diabetic mice. Although there was no effect on hindlimb perfusion at the end of this treatment, Exenatide administration acutely increased tibial blood flow. While Exenatide treatment did not restore the impaired bone strength, intrinsic properties of the matrix, such as collagen maturity, were improved. The effects of Exenatide on in vitro bone formation were further investigated in primary osteoblasts cultured under high-glucose conditions, showing that Exenatide reversed the impairment in bone formation induced by glucose. In conclusion, Exenatide improves trabecular bone mass by increasing bone formation and could protect against the development of skeletal complications associated with T2DM.Entities:
Keywords: blood flow; bone quality; db/db mice; exenatide; skeleton; type 2 diabetes
Year: 2017 PMID: 29209277 PMCID: PMC5701968 DOI: 10.3389/fendo.2017.00327
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Figure 1Body mass and blood glucose in db/db and control mice. Body mass and blood glucose levels were measured weekly in db/db and lean mice. Injections of Exenatide started at week 9 and continued daily for 4 weeks. (A) Body mass in relation to age in lean, diabetic, and Exenatide-treated mice from 7 to 13 weeks of age. (B) Blood glucose levels in lean, diabetic, and Exenatide-treated mice from 7 to 13 weeks of age. Bars represent mean ± SD for n = 10 mice/group, ****P < 0.0001 saline-treated diabetic versus saline-treated lean; #P < 0.05; ####P < 0.0001 Exenatide-treated diabetic versus saline-treated diabetic mice.
Figure 2Acute and chronic effects of Exenatide on hindlimb blood flow in db/db mice and control mice. (A,B) Representative images of mouse hindlimb perfusion, obtained by laser Doppler imaging (LDI). (A) Blood flow imaging of db/db mice with saline injection versus Exenatide. Images were acquired after a 25 min infusion of saline or Exenatide (10 μg/kg/day), (B) blood flow imaging of untreated lean mice versus db/db mice. Images were acquired after the 4 weeks of treatment. The colors in the heat maps indicate the maximum (red) and the minimum (blue) levels of perfusion, expressed in arbitrary units, representing the total blood flux (combination of velocity and concentration of red blood cells). (C,D) Time course graph of the average hindlimb perfusion monitored by LDI after Exenatide injection in db/db (C) and lean (D) mice. Exenatide (10 µg/kg) and saline were injected to mice after 8 min of baseline recording. Values are presented as mean ± SEM of n = 10 mice/group, *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 versus saline. (E) Differences in hindlimb blood flow measured by LDI between the groups after 4-week treatment with Exenatide. Bars represent mean ± SD of n = 10 mice/group, ****P < 0.0001 versus lean mice.
Measurements of trabecular and cortical bone architecture in 13-week-old db/db and lean mice treated with either Ex-4 or saline.
| Parameters | Lean saline | Lean Ex-4 | db/db saline | db/db Ex-4 |
|---|---|---|---|---|
| BV/TV (%) | 7.21 ± 1.37 | 7.83 ± 1.29 | 3.35 ± 0.51**** | 5.00 ± 0.78## |
| Tb.Th (μm) | 57.4 ± 2.9 | 58.1 ± 3.3 | 45.3 ± 2.2**** | 49.1 ± 1.8## |
| Tb.N (/mm) | 1.23 ± 0.24 | 1.36 ± 0.21 | 0.74 ± 0.12**** | 1.02 ± 0.18## |
| Tb.Pf (/mm) | 17.00 ± 4.78 | 15.25 ± 2.72 | 28.89 ± 2.10**** | 20.62 ± 2.94#### |
| SMI | 1.9 ± 0.21 | 1.78 ± 0.15 | 2.18 ± 0.09**** | 1.93 ± 0.13## |
| Tb.Sp (mm) | 0.46 ± 0.03 | 0.45 ± 0.04 | 0.49 ± 0.03 | 0.46 ± 0.04 |
| BV/TV (%) | 11.25 ± 3.01 | 12.86 ± 3.06 | 4.53 ± 1.30**** | 7.70 ± 1.21# |
| Tb.Th (μm) | 39.5 ± 7.2 | 39.5 ± 4.3 | 26.3 ± 3.8**** | 34.4 ± 4.0## |
| Tb.N (/mm) | 3.47 ± 0.39 | 3.68 ± 0.46 | 1.68 ± 0.35**** | 2.31 ± 0.37## |
| Tb.Sp (mm) | 0.27 ± 0.05 | 0.25 ± 0.05 | 0.59 ± 0.10**** | 0.44 ± 0.10## |
| Tt.Ar (mm2) | 1.00 ± 0.09 | 0.97 ± 0.08 | 0.85 ± 0.08** | 0.80 ± 0.09 |
| Tt.Pm (mm) | 3.99 ± 0.19 | 3.93 ± 0.15 | 3.64 ± 0.18** | 3.54 ± 0.18 |
| Ct.Ar (mm2) | 0.57 ± 0.06 | 0.55 ± 0.08 | 0.43 ± 0.06*** | 0.40 ± 0.07 |
| Ecc | 0.55 ± 0.06 | 0.54 ± 0.07 | 0.46 ± 0.04* | 0.45 ± 0.09 |
| 0.14 ± 0.03 | 0.13 ± 0.03 | 0.09 ± 0.02*** | 0.08 ± 0.02 | |
| Ct.Th (mm) | 0.17 ± 0.01 | 0.17 ± 0.02 | 0.14 ± 0.02*** | 0.13 ± 0.02 |
Measurements of trabecular architecture were performed in the proximal tibial metaphysis of db/db and lean mice using micro-CT or histomorphometry. Measurements of cortical architecture were made using micro-CT in the tibial midshaft diaphysis of db/db and lean mice.
BV/TV, bone volume percent; Tb.N, trabecular number; Tb.Pf, trabecular pattern factor; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; SMI, structure model index; Tt.Ar, tissue area; Tt.Pm, tissue perimeter; Ct.Ar, bone area; Ecc, eccentricity; I.
Mean ± SD of n = 10 mice/group. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 versus lean saline. .
Figure 3Effect of Exenatide on bone turnover parameters in db/db and control mice. Measurements were performed by bone histomorphometry on the trabecular region of tibial sections from 13-week-old db/db and lean mice treated with either Exenatide (10 μg/kg/day) or saline. (A) Bone formation rate (BFR). (B) Mineral apposition rate (MAR). (C) Mineralizing surfaces MS/BS. (D) Tartrate-resistant acid phosphatase (TRAP)-positive osteoclastic surfaces per millimeter of trabecular bone surface. Bars represent mean ± SD of n = 10 mice/group, **P < 0.01, ***P < 0.001, ****P < 0.0001 versus lean Sal; ##P < 0.01, ###P < 0.001 versus diabetic Sal.
Figure 4Effects of Exenatide on bone nodule formation in vitro under normal and high-glucose conditions. Mouse primary osteoblasts were isolated from calvaria of 2–3 days old pups and cultured for 28 days in six-well plates in osteogenic medium (with addition of ascorbate and β-glycerophosphate) in either normal (5.5 mM) or high- (22 mM) glucose concentration. Exenatide was added to the cells in normal and high-glucose conditions at various concentrations (0, 25, 50, and 100 nM). A control with 22 mM of mannitol was used as an osmotic control to ensure that changes in bone formation is due to glucotoxicity rather than hyperosmolarity. Mineralized nodules representing bone formation were scanned and observed unstained. Quantification of mineralization was performed using Image J. (A) Imaging of bone nodules using contrasting color on photoshop to visualize the bone nodules that appear in white. (B) Quantification of the area of bone formation by osteoblasts cultured with glucose and Exenatide. Mean ± SD of six wells/group. ****P < 0.0001 versus low glucose condition; ####P < 0.0001, ###P < 0.001 versus no Exenatide. Experiments were performed three times in triplicates and graphs are representative of one experiment.
Figure 5Effect of Exenatide on trabecular bone strength in db/db and control mice. Mechanical parameters were recorded in whole left femur using three-point bending in 13-week-old db/db and lean mice treated with either Exenatide (10 μg/kg/day) or saline. (A) Examples of load-displacement curves. (B) Ultimate load. (C) Ultimate displacement. (D) Stiffness. (E) Work-to-failure. Bars represent mean ± SD of n = 10 mice/group, *P < 0.05, **P < 0.01, ***P < 0.001 versus lean Sal.
Figure 6Effect of Exenatide on bone mineral density distribution (BMDD) in db/db and control mice. Quantitative backscattered electron imaging was employed to determine the BMDD in tibial methylmethacrylate-embedded blocks from 13-week-old db/db and lean mice treated with either Exenatide (10 μg/kg/day) or saline. (A) Representative calcium (Ca) map. (B) Characterization of BMDD by Ca width. (C) Characterization of BMDD by Ca mean. (D) Characterization of BMDD by Ca peak. Bars represent mean ± SD of n = 10 mice/group, *P < 0.05 versus lean Sal; ###P < 0.001 versus diabetic Sal.
Figure 7Effect of Exenatide on tissue material properties assessed at bone formation sites in db/db and control mice. Measurements were performed by Fourier-transform infrared microscopy between the fluorescent labels of the trabecular region of tibial sections in 13-week-old db/db and lean mice treated with either Exenatide or saline. (A) Mineral-to-matrix ratio. (B) Mineral maturity. (C) Carbonate-to-phosphate ratio. (D) Collagen maturity index. Bars represent mean ± SD of n = 10 mice/group, *P < 0.05, **P < 0.01 versus lean Sal; ###P < 0.001 versus diabetic Sal.